During his career in Soviet bioweaponry development in the late 1970s and 1980s, Alibekov managed projects that included weaponizing glanders and Marburg hemorrhagic fever, and created Russia's first tularemia bomb.[4] His most prominent accomplishment was the creation of a new "battle strain" of anthrax, known as "Strain 836", later described by the Los Angeles Times as "the most virulent and vicious strain of anthrax known to man".[5][4]
In 1992, he defected to the United States; he has since become an American citizen and made his living as a biodefense consultant, speaker, and entrepreneur. He had actively participated in the development of biodefense strategy for the U.S. government, and between 1998 and 2005 he testified several times before the U.S. Congress and other governments on biotechnology issues, saying he was “convinced that Russia’s biological weapons program has not been completely dismantled”.[3] In 1994, Alibek received a congressional award, a bronze Barkley medal awarded in recognition of distinguished public service and his contribution to world peace.
In 2002, Alibek told United Press International that there is concern that monkeypox could be engineered into a biological weapon.[3]
Ohio-based Locus Fermentation Solutions hired Alibek in 2015 as executive vice president for research and development of biologically active molecules for different applications.[6]
Early life and education
Alibek was born Kanat Alibekov in Kauchuk, in the Kazakh SSR of the Soviet Union (present-day Kazakhstan), to a Kazakh family. He grew up in Almaty, the republic's former capital. He is a certified oncologist,[7] a doctor of science,[8] doctor of philosophy [9] and a doctor of medicine.[10]
Career
Alibek's academic performance while studying military medicine at the Tomsk Medical Institute and his family's noted patriotism led to his selection to work for Biopreparat, the secret biological weapons program overseen by the Soviet Union's Council of Ministers. His first assignment in 1975 was to the Eastern European Branch of the Institute of Applied Biochemistry (IAB) near Omutninsk, a combined pesticide production facility and reserve biological weapons production plant intended for activation in a time of war. At Omutninsk, Alibek mastered the art and science of formulating and evaluating nutrient media and cultivation conditions for the optimization of microbial growth. While there, he expanded his medical school laboratory skills into the complex skill set required for industrial-level production of microorganisms and their toxins.[11]
After a year at Omutninsk, Alibek was transferred to the Siberian Branch of the IAB near Berdsk (another name of the branch was the Berdsk scientific and production base). With the assistance of a colleague, he designed and constructed a microbiology research and development laboratory that worked on techniques to optimize the production of biological formulations.
After several promotions, Alibek was transferred back to Omutninsk, where he rose to the position of deputy director. He was soon transferred to the Kazakhstan Scientific and Production Base in Stepnogorsk (another reserve BW facility) to become the new director of that facility. Officially, he was deputy director of the Progress Scientific and Production Association, a manufacturer of fertilizer and pesticide.
At Stepnogorsk, Alibek created an efficient industrial scale assembly line for biological formulations. In a time of war, the assembly line could be used to produce weaponized anthrax. Continued successes in science and biotechnology led to more promotions, which resulted in a transfer to Moscow.[12]
Biopreparat
In Moscow, Alibek began his service as deputy chief of the biosafety directorate at Biopreparat. He was promoted in 1988 to first deputy director of Biopreparat, where he not only oversaw the biological weapons facilities but also the significant number of pharmaceutical facilities that produced antibiotics, vaccines, sera, and interferon for the public.
In response to a Spring 1990 announcement that the Ministry of Medical and Microbiological Industry was to be reorganized, Alibek drafted and forwarded a memo to then General Secretary Mikhail Gorbachev proposing the cessation of Biopreparat's biological weapons work. Gorbachev approved the proposal, but an additional paragraph was secretly inserted into Alibek's draft, resulting in a presidential decree that ordered the end of Biopreparat's biological weapons work but also required them to remain prepared for future bioweapons production.
Alibek used his position at Biopreparat and the authority granted to him by the first part of the decree to begin the destruction of the biological weapons to dismantle biological weapons production and testing capabilities at a number of research and development facilities, including Stepnogorsk, Kol'tsovo, Obolensk, and others. He also negotiated a concurrent appointment to a Biopreparat facility called Biomash. Biomash designed and produced technical equipment for microbial cultivation and testing. He planned to increase the proportion of its products sent to hospitals and civilian medical laboratories beyond the 40% allocated at the time.[12]
Following the dissolution of the Soviet Union in December 1991, Alibek was subsequently placed in charge of intensive preparations for inspections of Soviet biological facilities by a joint American and British delegation. But when he participated in the subsequent Soviet inspection of American facilities, his suspicion that the U.S. did not have an offensive bioweapons program was confirmed before his return to Russia. In January 1992, not long after his return from the U.S., Alibek protested against Russia's continuation of bioweapons work and resigned from both the Russian Army and Biopreparat.
Immigration to the United States
In October 1992, Alibek and his family emigrated to the United States.[12] After moving to the U.S., Alibekov provided the government with a detailed accounting of the former Soviet biological weapons program. During a CIA debriefing, Alibek described the Soviet efforts to weaponize a particularly virulent smallpox strain, producing hundreds of tons of the virus that could be disseminated with bombs or ballistic missiles.[13] Information about the Soviet biological weapons program had already been provided in 1989 by the defected scientist Vladimir Pasechnik.
Alibekov has testified before the U.S. Congress several times and has provided guidance to U.S. intelligence, policy, national security, and medical communities.
He was the impetus behind the creation of a biodefense graduate program at the Schar School of Policy and Government at George Mason University, serving as Distinguished Professor of Medical Microbiology and the program's Director of Education. He also developed the plans for the university's biosafety level three (BSL-3) research facility and secured $40 million of grants from the federal and state governments for its construction.[12]
From 1993 to 1999, Alibek took on multiple R&D roles, including a visiting scientist at the National Institute of Health, researching novel antigenic, potentially immunogenic substances for the development of tuberculosis vaccine; project manager at SRS Technologies where he researched, analyzed and developed detailed synthesis reports regarding the biotechnological of foreign countries; and program manager at Battelle Memorial Institute overseeing research projects in medical biotechnology, biosynthesis and fermentation equipment.
In 1999, Alibek published an autobiographical account of his work in the Soviet Union and his defection.[14]
Reporting the prospect of Iraq gaining the ability to get hold of smallpox or anthrax, Alibek said, "there is no doubt that Saddam Hussein has weapons of mass destruction." However, no biological weapons were later found in Iraq.
Entrepreneur and research administrator
Alibek was president, chief scientific officer, and chief executive officer at AFG Biosolutions, Inc in Gaithersburg, Maryland,[15] where he and his scientific team continued their development of advanced solutions for antimicrobial immunity. Motivated by the lack of affordable anti-cancer therapies available in Eastern Europe and Central Asia, AFG was using Alibek's biotechnology experience to plan, build, and manage a new pharmaceutical production facility designed specifically to address this problem.
Alibek created a new pharmaceutical production company, MaxWell Biocorporation (MWB), in 2006 and served as its chief executive officer and president. Based in Washington, D.C., with several subsidiaries and affiliates in the U.S. and Ukraine, MWB's main stated goal is create a new, large-scale, high-technology, ultra-modern pharmaceutical fill-and-finish facility in Ukraine. Off-patent generic pharmaceuticals produced at this site are intended to target severe oncological, cardiological, immunological, and chronic infectious diseases.
Construction of the Boryspil facility began in April 2007 and was completed in March 2008; initial production was scheduled to begin in 2008. The stated intention was that high-quality pharmaceuticals would be produced and become an affordable source of therapy for millions of underprivileged who currently have no therapeutic options.[16] Abilek stepped down as President of MWB in the summer of 2008 shortly after the facility opened.
Alibek's main research focus was developing novel forms of therapy for late-stage oncological diseases and other chronic degenerative pathologies and disorders. He focuses on the role of chronic viral and bacterial infections in causing age-related diseases and premature aging. Additionally, he develops and implements novel systemic immunotherapy methods for late-stage cancer patients.[16]
Throughout his career, Alibek has published nine research articles on the role of infectious diseases in cancer.[17]
Work in Kazakhstan
In 2010, Alibek was invited to begin working in Kazakhstan as a head of the Department of Chemistry and Biology at the School of Science and Technology of Nazarbayev University in Astana, where he was engaged in the development of anti-cancer drugs and life-prolonging drugs, and was chairman of the board of the Republican Scientific Center for Emergency Medical Care and headed the National Scientific Center for Oncology and Transplantation. During his stay, he published a number of articles in research journals and taught various courses in various fields of biology and medicine. He focused on a possible role of chronic infections, metabolic disorders, and immunosuppression on cancer development. In 2011, he was awarded a prize from the Deputy Prime Minister for his contribution to the development of the educational system in Kazakhstan. In 2014, he was awarded a medal by the Minister of Education and Science of Kazakhstan for his contribution to research in Kazakhstan. He continues his work as an administrative manager of a research and medicine and education professor.
However, after seven years, no significant scientific results from Alibek's work developed. During these seven years, Alibek received more than 1 billion Tenge from the budget for "New Systemic Therapy for Cancer Tumors" project he tried to implement. The promising Swedish technique has remained a common concept, a panacea for cancer treatment has not appeared. Three submitted Alibekov patent applications for registration were rejected by the National Institute of Intellectual Property of the Ministry of Justice of the Republic of Kazakhstan since there was no novelty.[18]
In 2016, Alibek was chosen as one of the nominees in the "Science" category of the national project El Tulgasy, which was designed to select the most significant citizens of Kazakhstan who are associated with national achievements. More than 350,000 people voted in this project, and Alibek was voted 10th place in his category.[19]
COVID-19
Alibek has experience in vaccine development for pandemics. In 2006, his article on new principles for developing these vaccines was published in Future Medicine.[20]
In January 2020, Alibek issued a warning about COVID-19 and its potential as a global problem.[21] His research on safe methods of protection against the virus ahead of a vaccine was later published in the journal Research Ideas and Outcomes (RIO).[22] He also wrote two chapters on methods to protect against the COVID-19 pandemic in the book Defending Against Biothreats: What We Can Learn from the Coronavirus Pandemic to Enhance U.S. Defenses Against Pandemics and Biological Weapons.[23]
In 2021, Alibek offered a free seminar on the antiviral biodefence in the world of epidemic uncertainties.[24]
Autism research
Starting in 2007, Alibek began researching autism based on his background as a board-certified oncologist and his own personal connection to the disorder through his daughter, Mary. He supports the idea that the disorder is the result of prenatal viral and bacterial infections. Multiple studies have been conducted with patients that have autism spectrum disorder, including a 2018-2019 study with 57 patients, a 2021-2023 study with 142 patients and a 2023 study with 32 patients. In addition, more than 1,000 children have been treated using the protocol. His patients are located predominantly in nations in the former Soviet Union and Ukraine, and he consults mainly using free telemedicine services. During these studies, specific inflammation markers along with biochemical and neuropsychiatric parameters were identified as an objective measure of improvement in and a reduction of symptoms. Alibek has published 6 studies in peer-reviewed journals about the causes and treatment of Autism, and has one issued U.S. patent and three U.S. patent filings on his novel approach to treatment.[25]
Criticism
In a September 2003 news release, Alibek and another professor suggested, based on their laboratory research, that the smallpox vaccination might increase a person's resistance to HIV. The work was rejected after peer review by the Journal of the American Medical Association and The Lancet and is no longer being pursued. According to smallpox expert and former White House science advisor Donald Henderson, "This is a theory that... does not hold up at all, and it does not make any sense from a biologic point of view...This idea...was straight off the wall. I would put no credence in it at all." In 2010, an article coauthored by Alibek appeared in Biomed Central - Immunology, a scientific journal, that outlined the results of their research showing that prior immunization with the vaccine Dryvax may confer resistance to HIV replication.[26]
Alibek also has promoted "Dr. Ken Alibek's Immune System Support Formula," a dietary supplement sold over the Internet. It contains vitamins, minerals, and a proprietary bacterial mix that will purportedly "bolster the immune system".[27]
Personal life
Alibek has a wife and five children (two sons and three daughters); one of his daughters is autistic.
Alibek, Ken and Steven Handelman (1999), Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World – Told from Inside by the Man Who Ran It, Random House, ISBN0-385-33496-6.
"The Anthrax Vaccine: Is It safe? Does it Work?" (2002), Reviewer. National Academy Press, Washington, D.C., Institute of Medicine.
Biological Threats and Terrorism: Assessing the Science and Response Capabilities (2002), Workshop Summary, Contributor. National Academy Press, Washington, D.C., Institute of Medicine.
Weinstein, R.S. and K. Alibek (2003), Biological and Chemical Terrorism: A Guide for Healthcare Providers and First Responders, Thieme Medical Publishing, New York.
Alibek, K., et al. (2003), Biological Weapons, Bio-Prep, Louisiana.
Fong, I. and K. Alibek (2005), Bioterrorism and Infectious Agents: A New Dilemma for the 21st Century, Springer.
Fong, I. and K. Alibek (2006), New and Evolving Infections of the 21st Century, Springer.
Fleitz, Alibek, Bryen, Rosett, Chang, DeSutter, Elliott, Faddis, Geraghty, Gibson (2020), Defending Against Biothreats: What We Can Learn from the Coronavirus Pandemic to Enhance U.S. Defenses Against Pandemics and Biological Weapons
Book chapters
"Firepower in the Lab: Automation in the Fight Against Infectious Diseases and Bioterrorism" (2001), Chapter 15 of Biological Weapons: Past, Present, and Future, National Academy Press, Washington, D.C., Institute of Medicine.
Jane's Chem-Bio Handbook (2002), Second Edition, F. R. Sidell, W. C. Patrick, T. R. Dashiell, K. Alibek, Jane's Information Group, Alexandria, VA.
K. Alibek, C. Lobanova, "Modulation of Innate Immunity to Protect Against Biological Weapon Threat" (2006). In: Microorganisms and Bioterrorism, Springer.
2014 Kazakhstan Government's Prime Minister Award “For Distinguished Contribution to Science”
2011 Kazakhstan Government's Vice Prime Minister Award “For the Development of Kazakhstan Education System”
2007 “Panacea Award” for Innovations in Medical and Pharmaceutical Industries, Kyiv (Ukraine)
2005 Lecturer for on a “Russian-American Security Program of Harvard University’s John Kennedy Center for Government Studies
2005 Senior Fellow, Center for Advanced Defense Studies, Washington DC
2004 Outstanding Faculty Member Award, George Mason University
2002 Business Forward Magazine Award: “Deals of the Year” for One of the Largest Federal Research Contracts for Small Businesses
2000 (Davos, Switzerland), 2002 (New York) Invited speaker to the World Economic Forum
1994 Congressional Award: Bronze medal named after Albane W. Barkley - Awarded by the U.S. Government in Recognition of Distinguished Public Service
1989 A Colonel of Medical Services, awarded by the USSR's Minister of Defense
1983 Medal “For Combat Merits” by the USSR's Minister of Defense
Related Research Articles
Biological warfare, also known as germ warfare, is the use of biological toxins or infectious agents such as bacteria, viruses, insects, and fungi with the intent to kill, harm or incapacitate humans, animals or plants as an act of war. Biological weapons are living organisms or replicating entities. Entomological (insect) warfare is a subtype of biological warfare.
Bioterrorism is terrorism involving the intentional release or dissemination of biological agents. These agents include bacteria, viruses, insects, fungi, and/or their toxins, and may be in a naturally occurring or a human-modified form, in much the same way as in biological warfare. Further, modern agribusiness is vulnerable to anti-agricultural attacks by terrorists, and such attacks can seriously damage economy as well as consumer confidence. The latter destructive activity is called agrobioterrorism and is a subtype of agro-terrorism.
Biodefense refers to measures to counter biological threats, reduce biological risks, and prepare for, respond to, and recover from bioincidents, whether naturally occurring, accidental, or deliberate in origin and whether impacting human, animal, plant, or environmental health. Biodefense measures often aim to improve biosecurity or biosafety. Biodefense is frequently discussed in the context of biological warfare or bioterrorism, and is generally considered a military or emergency response term.
The All-Union Science Production Association Biopreparat was a Soviet agency created in April 1974, which spearheaded the largest and most sophisticated offensive biological warfare program the world has ever seen. It was a vast, ostensibly civilian, network employing 30–40,000 personnel and incorporating five major military-focused research institutes, numerous design and instrument-making facilities, three pilot plants and five dual-use production plants. The network pursued major offensive research and development programs which genetically engineered microbial strains to be resistant to an array of antibiotics. In addition, bacterial agents were created with the ability to produce various peptides, yielding strains with wholly new and unexpected pathogenic properties.
The State Research Center of Virology and Biotechnology VECTOR, also known as the Vector Institute, is a biological research center in Koltsovo, Novosibirsk Oblast, Russia. It has research facilities and capabilities for all levels of biological hazard, CDC levels 1–4. It is one of two official repositories for the now-eradicated smallpox virus, and was part of the system of laboratories known as the Biopreparat.
The Demon in the Freezer is a 2002 nonfiction book on the biological weapon agents smallpox and anthrax and how the American government develops defensive measures against them. It was written by journalist Richard Preston, also author of the best-selling book The Hot Zone (1994), about ebolavirus outbreaks in Africa and Reston, Virginia and the U.S. government's response to them.
Vozrozhdeniya Island was an island in the Aral Sea. The former island's territory is split between Uzbekistan and Kazakhstan. In 1954, the Soviet Union constructed a biological weapons test site called Aralsk-7 there and on the neighbouring Komsomolskiy Island, which also no longer exists.
The United States Army Medical Research Institute of Infectious Diseases is the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare. It is located on Fort Detrick, Maryland, near Washington, D.C., and is a subordinate lab of the United States Army Medical Research and Development Command (USAMRDC), headquartered on the same installation.
On 2 April 1979, spores of Bacillus anthracis were accidentally released from a Soviet military research facility in the city of Sverdlovsk, Soviet Union. The ensuing outbreak of the disease resulted in the deaths of at least 68 people, although the exact number of victims remains unknown. The cause of the outbreak was denied for years by the Soviet authorities, which blamed the deaths on consumption of tainted meat from the area, and subcutaneous exposure due to butchers handling the tainted meat. The accident was the first major indication in the Western world that the Soviet Union had embarked upon an offensive programme aimed at the development and large-scale production of biological weapons.
The Biodefense and Pandemic Vaccine and Drug Development Act of 2005, nicknamed "Bioshield Two" and sponsored by Senator Richard Burr, aims to shorten the pharmaceutical development process for new vaccines and drugs in case of a pandemic, and to protect vaccine makers and the pharmaceutical industry from legal liability for vaccine injuries. The proposed bill would create a new federal agency, the Biomedical Advanced Research and Development Agency (BARDA), that would act "as the single point of authority" to promote advanced research and development of drugs and vaccines in response to bioterrorism and natural disease outbreaks, while shielding the agency from public Freedom of Information Act (FOIA) requests. BARDA would be exempt from long-standing open records and meetings laws that apply to most government departments.
The National Biodefense Analysis and Countermeasures Center (NBACC) is a government biodefense research laboratory created by the U.S. Department of Homeland Security (DHS) and located at the sprawling biodefense campus at Fort Detrick in Frederick, MD, USA. The NBACC is the principal U.S. biodefense research institution engaged in laboratory-based threat assessment and bioforensics. NBACC is an important part of the National Interagency Biodefense Campus (NIBC) also located at Fort Detrick for the US Army, National Institutes of Health and the US Department of Agriculture.
Jeanne Harley Guillemin was an American medical anthropologist and author, who for 25 years taught at Boston College as a professor of Sociology and for over ten years was a senior fellow in the Security Studies Program at Massachusetts Institute of Technology. She was an authority on biological weapons and published four books on the topic.
The Soviet Union covertly operated the world's largest, longest, and most sophisticated biological weapons program, thereby violating its obligations as a party to the Biological Weapons Convention of 1972. The Soviet program began in the 1920s and lasted until at least September 1992 but has possibly been continued by Russian Federation after that.
The Project Bioshield Act was an act passed by the United States Congress in 2004 calling for $5 billion for purchasing vaccines that would be used in the event of a bioterrorist attack. This was a ten-year program to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. A key element of the Act was to allow stockpiling and distribution of vaccines which had not been tested for safety or efficacy in humans, due to ethical concerns. Efficacy of such agents cannot be directly tested in humans without also exposing humans to the chemical, biological, or radioactive threat being treated, so testing follows the FDA Animal Rule for pivotal animal efficacy.
The Biomedical Advanced Research and Development Authority (BARDA)' is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.
The Stepnogorsk Scientific and Technical Institute for Microbiology, also known as the Scientific Experimental and Production Base, was one of the premier biological warfare facilities operated by the Soviet Union. It was the only Biopreparat facility to be built outside of Russia proper, and one of the few ever visited officially by Western experts. As of 1998 the site conducted civilian biological research overseen by director Vladimir Bugreyev. At the time the United States Department of State and the U.S. Civilian Research & Development Foundation provided significant funds supporting civilian research at Stepnogorsk.
The United States Biological Defense Program—in recent years also called the National Biodefense Strategy—refers to the collective effort by all levels of government, along with private enterprise and other stakeholders, in the United States to carry out biodefense activities.
The Alliance for Biosecurity is a consortium of companies that develop products to respond to national security threats, including bioterrorism pathogens and emerging infectious diseases. It is headquartered in Washington DC.
Anthrax weaponization is the development and deployment of the bacterium Bacillus anthracis or, more commonly, its spore, as a biological weapon. As a biological weapon, anthrax has been used in biowarfare and bioterrorism since 1914. However, in 1975 the Biological Weapons Convention prohibited the "development, production and stockpiling" of biological weapons. It has since been used in bioterrorism.
↑ Alibek, Ken and Stephen Handelman (1999), Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World – Told from Inside by the Man Who Ran It, Delta (2000) ISBN0-385-33496-6
↑ Alibek K, Farmer S, Tskhay A, Moldakozhayev A, Isakov T (2019) Etiotropic and Pathogenetic Therapy of Autism Spectrum Disorder: Case Series of 6 Children. J Neurol Psychiatr Disord 1(1): 105; Alibek K, Farmer S, Tskhay A, Moldakozhayev A and Isakov T (2019) Prevalence of Prenatal, Neonatal and Postnatal Complications among Healthy Children and Children Diagnosed with ASD in Central Asia and Eastern Europe. J Gynecol Neonatal 2(1): 103; Kenneth Alibek, Sean Farmer, Albina Tskhay, Alibek Moldakozhayev and Kira Alibek., et al (2019) Tendencies in Changes of Blood Parameters and in Autistic Symptoms Improvements as a Result of Antiviral Treatment: Descriptive Case Series of 11 Children from Eastern Europe and Central Asia. J Clin Case Rep Clin Res 1(1): 102; Kenneth Alibek, Sean Farmer, Albina Tskhay, Alibek Moldakozhayev and Kira Alibek., et al (2019) The Role of Infection, Inflammation and Genetic Alterations in ASD Etiopathogenesis: A Review. J Neurol Psychiatr Disord 2(1): 105; Alibek K, Farmer S, Tskhay A, Moldakozhayev A, Isakov T (2019) Treatment of Chronic and Latent Infections Combined with Nutritional Supplementation Positively Affects Quality of Life of ASD Children: Series of 30 Cases. J Nutr Diet Suppl 3(1): 102; Alibek K, Niyazmetova L, Farmer S, Isakov T (2022) Persistent Inflammation Initiated by TORCH Infections and Dysbiotic Microbiome in Autism Spectrum Disorders: A Prospect for Future Interventions. Research Ideas and Outcomes 8: e91179.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
Soviet Union 
